TrialJournal of the National Cancer Institute2020

Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.

You-Lin Qiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.